Affiliation:
1. Division of Cardiovascular Medicine, University of Manchester and Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K
2. Division of Regenerative Medicine, University of Manchester, Manchester, U.K
Abstract
OBJECTIVE—To assess the relevance of vascular endothelial growth factor (VEGF) in the maintenance of peripheral nerve integrity in diabetic neuropathy we have assessed the expression of VEGF and intra-epidermal nerve fiber density (IENFD) in skin biopsy samples from diabetic patients.
RESEARCH DESIGN AND METHODS—Fifty-three diabetic patients and 12 nondiabetic control subjects underwent neurological evaluation, electrophysiology, quantitative sensory, and autonomic function testing. Dermal blood flow responses were evaluated with laser Doppler flowmetry. Skin biopsies were performed on the dorsum of the foot, and IENFD was quantified and compared with the expression of vascular endothelial growth factor A (VEGF-A), its receptor vascular endothelial growth factor receptor 2 (VEGFR-2), hypoxia-inducible factor 1α (HIF-1α), and microvessel density.
RESULTS—IENFD decreased progressively with increasing severity of diabetic neuropathy (P < 0.001). The dermal blood flow response to acetylcholine was reduced in diabetic patients with mild and moderate neuropathy (P < 0.01), and the intensity of staining for epidermal VEGF-A was significantly reduced in diabetic patients compared with control subjects (P < 0.01). Epidermal HIF-1α and VEGFR-2 expression did not differ between groups.
CONCLUSIONS—Progressive endothelial dysfunction, a reduction in VEGF expression, and loss of intra-epidermal nerve fibers occurs in the foot skin of diabetic patients with increasing neuropathic severity.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference30 articles.
1. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615–1625, 2005
2. Hobson MI, Green CJ, Terenghi G: VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat 197 (Pt. 4):591–605, 2000
3. Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M, Fink DJ: HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 12:1377–1384, 2005
4. Price SA, Dent C, Duran-Jimenez B, Liang Y, Zhang L, Rebar EJ, Case CC, Gregory PD, Martin TJ, Spratt SK, Tomlinson DR: Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 55:1847–1854, 2006
5. Kipnes MS, Ando DG, Cornblath DR: Single treatment, phase 1b placebo controlled trial of a zinc finger growth factor (ZFP) activator (SB-509) of a vascular endothelial growth factor (VEGF) in subjects with diabetic neuropathy (DN) (Abstract 1989-PO). Presented at the 66 annual meeting of the American Diabetes Association, 2006
Cited by
109 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献